Bharat Biotech COVID-19 vaccine claimed to have 80.6% efficacy
'Shot well tolerated in participants; adverse events balanced between vaccine and placebo arms of the trial'
WATCH: How Serum Institute of India is pricing Covishield
Vaccination against COVID-19 will undergo major modifications next month. Here’s a quick glance.
Covaxin has not got emergency use approval from WHO since 6 months. Know the process here
The approval is stuck in the final fifth stage of the process when clinical data on safety, efficacy, quality and risk management plan are evaluated
COVID-19: India trips on its patent waiver proposal
New Delhi has not backed its WTO proposal to suspend intellectual property rights on COVID-19 pharma products with robust action
Confronting head-on the vexed pricing of COVID -19 vaccines
It would cost anything between Rs 13,821 crore to Rs 1,10,568 crore to vaccinate the 20-44 age population
What are India’s options for a booster dose of COVID-19 vaccine
Hyderabad-based Biological E’s Corbevax and SII’s Covovax, both of which are protein-based vaccines, are India’s best bet for a …
WHO finally gives emergency use nod for Covaxin
Those administered indigenous Indian vaccine against COVID-19 can now travel abroad unhindred
Lateral thoughts: COVID-19 vaccines and a game of chance
Would you be compensated for adverse reactions to the COVID-19 vaccines?
Hesitancy, logistical challenges behind low turnout at vaccination camps in West Bengal
State is vaccinating health workers beyond the online list generated by Co-WIN app to attain target
India starts COVID-19 vaccination drive; Modi calls doubts over vaccine ‘propaganda’
Prime Minsiter urges people to not drop caution even after being vaccinated
Omicron threat: How fast is India vaccinating against COVID-19
Rate too slow to meet target of vaccinating every eligible by end of year. The question is: Can Omicron further derail India’s fight …
Can nasal vaccines shield against breakthrough infections?
New study argues that nasal vaccines may be necessary to achieve more robust immunity and protection from reinfection by future variants
Resurgence of COVID-19 cases serious concern: Centre
‘Clinical trial mode’ condition of Covaxin manufactured by Bharat Biotech International taken off; Covaxin granted licence similar to …
A new study says COVID-19 vaccination is not associated with a heart attack risk
About 1,002 patients who experienced a heart attack had been vaccinated with Covishield and the rest of the 84 with Covaxin
No mixing of vaccines in India for booster dose. What do experts say?
Studies point to better protection with mixed doses; experts call data ‘fragmentary’
Bhopal Covaxin trial participants allege side-effects, irregularities
Bhopal-based rights group writes to PM and Union health minister, demanding that ongoing Covaxin trial be halted there
Moderna’s brazen patent grab on a COVID-19 jab
The US administration is finally putting its foot down on the appropriation of public research by drug firms
Omicron variant: How should India deal with a fresh surge in COVID-19 cases?
India reported 1,700 omicron cases as of January 3
COVID-19 vaccine update: SC quizzes Centre on mandatory online registration, dual pricing
You keep saying digital India, digital India, but you are not aware of the ground realities: Justice Chandrachud
Bharat Biotech will begin clinical trials of Covaxin on 2-18 age group
The clinical trials will be conducted to evaluate Covaxin’s safety and efficacy on a population group left out of India’s current …
COVID-19 vaccines for all: India’s supply story deconstructed
Vaccination presents a way out of the COVID-19 mess India has landed in; but jabs are in short supply and there’s no clarity …
Vaccine production in South Africa: how an industry in its infancy can be developed
Only if investment is increased, sustained, and backed by political commitment, will the country have sufficient vaccine production capacity
COVID-19 vaccination drive hits a pause in Odisha’s 11 districts
After administering 0.3 million doses June 21, the state has run out of vaccines; the drive expected to resume July 2
COVID-19: First few peer reviewed studies suggest vaccine induced antibodies fail to protect from Omicron
The studies, published in Nature, covered Oxford-AstraZeneca vaccine, but not India’s indigenous Covaxin
Kerala starts COVID-19 vaccination; doubts, hesitancy, ignorance linger
The state will be holding back half of the vaccine stock it has received due to a shortfall